| 标题 |
Trifluridine–tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet Gastroenterology & Hepatology 作者:Thierry André; Alfredo Falcone; Yaroslav Shparyk; Fedor Moiseenko; Eduardo Polo-Marques; et al 出版日期:2022-12-02 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)